Showing results (121-130 of 154) with videos related to
Sort By:
Pageof 16
Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.Blood|May 28, 2017
T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine modelDavid M Woods, Karrune V Woan, Fengdong Cheng, et al.Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.Journal of Hematology & Oncology|January 7, 2022
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committeeJames L Januzzi, Joseph M Garasic, Scott E Kasner, et al.Journal of Leukocyte Biology|May 28, 2017
Essential role for histone deacetylase 11 (HDAC11) in neutrophil biologyEva Sahakian, Jie Chen, John J Powers, et al.Transplantation and Cellular Therapy|May 13, 2024
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell LymphomaYumeng Zhang, Ashley Rose, Sushmita Khadka, et al.Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.Pageof 16